Condition: Uterine Cervical Neoplasms · Sponsor: Hospital Israelita Albert Einstein
A total of 112 patients with locally advanced cervical cancer will be randomized 1:1 to standard therapy with cisplatin-based chemoradiation or nivolumab-ipilimumab induction followed by cisplatin-based chemoradiation. The primary outcome will be 3-year disease-free survival.
This description comes directly from the study's public registry record.
Diogo Bugano, MD · +55-11-2151-0240 · diogo.gomes@einstein.br
Always discuss trial participation with your own doctor first.
| CRIO -Centro Regional Integrado de Oncologia | Fortaleza, Ceará, Brazil | Recruiting |
| Clinica AMO | Salvador, Estado de Bahia, Brazil | Recruiting |
| Hospital das Clinicas da UFMG | Belo Horizonte, Minas Gerais, Brazil | Not Yet Recruiting |
| Hospital Erasto Gaertner | Curitiba, Paraná, Brazil | Not Yet Recruiting |
| Multi Oncoclinicas Recife | Recife, Pernambuco, Brazil | Recruiting |
| Hospital São Lucas - PUCRS | Porto Alegre, Rio Grande do Sul, Brazil | Not Yet Recruiting |
| Universidade Federal de Roraima | Boa Vista, Roraima, Brazil | Recruiting |
| CEPON - Florianópolis | Florianópolis, Santa Catarina, Brazil | Not Yet Recruiting |
| Hospital de Amor | Barretos, São Paulo, Brazil | Not Yet Recruiting |
| Hospital De Base de São José do Rio Preto - CIP São José | São José do Rio Preto, São Paulo, Brazil | Not Yet Recruiting |
| INCA - Instituto Nacional do Cancer | Rio de Janeiro, Brazil | Not Yet Recruiting |
| AC Camargo Cancer Center | São Paulo, Brazil | Not Yet Recruiting |
+ 2 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05492123